Search

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.

… Thursday, August 24, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email [email protected].

… Friday, June 10, 2016 A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on

Learn how to control weight gain during and after breast cancer treatment, from experts at MSK.

… Tuesday, August 12, 2025 Advances in breast cancer treatment mean more people than ever are surviving. There are nearly 4 million people living with breast cancer in the United States, and that number will continue to grow, thanks to lifesaving therapies. People diagnosed with breast cancer can help

The inaugural Kravis WiSE Symposium will take place virtually July 8-20, 2020. Each talk will be broadcast as part of the MSK Science Spotlight series, which is available via livestream and open to all.

… Tuesday, July 7, 2020 MSK has recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor ( WISE ) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and paving the way

New MSK research discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers; examined how tumor-associated macrophages might be turned against cancer; acquired new insights into joint inflammation in rheumatoid arthritis; developed a systems-level platform called epichaperomics to map changes in interactors among thousands of proteins involved in cancer-related processes; and investigated how artificial intelligence could help diagnose an invasive form of breast cancer.

… Thursday, June 29, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers

MSK has joined with 68 of the nation’s top cancer centers in issuing a statement urging increased HPV vaccination for the prevention of cancer. This statement, signed by MSK Physician-in-Chief and Chief Medical Officer José Baslega, MD, PhD, and colleagues at NCI-designated cancer centers across the country, calls upon the nation’s physicians, parents, and young adults to take advantage of this rare opportunity to prevent many types of cancer. MSK head and neck and gynecologic cancer experts are available to discuss the importance of the HPV vaccine and risks of HPV-related cancers. Please email [email protected] to arrange an interview.

… Wednesday, January 27, 2016 MSK has joined with 68 of the nation’s top cancer centers in issuing a statement urging increased HPV vaccination for the prevention of cancer. This statement, signed by MSK Physician-in-Chief and Chief Medical Officer José Baslega, MD, PhD, and colleagues at NCI-designated

Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons.

… Tuesday, March 2, 2021 Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons, according to our retrospective study published recently in the Journal of Surgical Oncology .  (1) Whether MIS is a safe and

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.

… Wednesday, January 17, 2018 Summary A new finding suggests that a genetic mistake in cancer cells known as chromosomal instability creates an inflammatory state within the cells. The cancer cells take advantage of this condition by hijacking pathways used by immune cells to migrate. This enables these

Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.

… Thursday, December 5, 2013 Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute , Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center that is designed to

The FDA has approved the first-ever treatment developed for low-grade serous ovarian cancer, a rare type of ovarian cancer.

… Monday, May 12, 2025 The first drug for a rare and difficult-to-treat type of  ovarian cancer has been granted  accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki TM Fakzynja TM Co-pack), was developed to treat low-grade serous